Compass Therapeutics (CMPX) Net Income towards Common Stockholders (2018 - 2026)

Compass Therapeutics has reported Net Income towards Common Stockholders for 9 years, with the latest figure at -$53.2 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 219.91% year-over-year to -$53.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$126.8 million (down 111.23% YoY) and the FY2025 annual result came in at -$152.0 million, down 31.06% from the prior year.
• Net Income towards Common Stockholders slipped to -$53.2 million in Q1 2026 per CMPX's latest filing, from -$18.1 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$7.2 million in Q1 2022 and troughed at -$53.2 million in Q1 2026.
• A 5-year average of -$16.4 million and a median of -$13.1 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2023 and 2026: Net Income towards Common Stockholders rose 16.79% in 2023, then tumbled 219.91% in 2026.
• Over 5 years, Net Income towards Common Stockholders stood at -$11.6 million in 2022, then dropped by 15.71% to -$13.4 million in 2023, then fell by 25.61% to -$16.8 million in 2024, then dropped by 7.32% to -$18.1 million in 2025, then plunged by 194.24% to -$53.2 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$53.2 million, -$18.1 million, and -$27.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.